Search results
Showing 1606 to 1620 of 8910 results
NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not provide an adequate evidence submission for committee decision-making.
Show all sections
Sections for TA972
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)
Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA923
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.